{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:04:18Z","timestamp":1792602258741,"version":"4.5.0"},"reference-count":161,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100008678","name":"Universit\u00e4t Leipzig","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008678","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40259-022-00549-3","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T05:03:37Z","timestamp":1661231017000},"page":"549-571","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":393,"title":["Therapeutic siRNA: State-of-the-Art and Future Perspectives"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7221-4222","authenticated-orcid":false,"given":"Maik","family":"Friedrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2778-6256","authenticated-orcid":false,"given":"Achim","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,23]]},"reference":[{"key":"549_CR1","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/35888","volume":"391","author":"A Fire","year":"1998","unstructured":"Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806\u201311.","journal-title":"Nature"},{"key":"549_CR2","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/35078107","volume":"411","author":"SM Elbashir","year":"2001","unstructured":"Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494\u20138.","journal-title":"Nature"},{"key":"549_CR3","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1101\/gad.927801","volume":"15","author":"RF Ketting","year":"2001","unstructured":"Ketting RF, Fischer SE, Bernstein E, Sijen T, Hannon GJ, Plasterk RH. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev. 2001;15:2654\u20139.","journal-title":"Genes Dev"},{"key":"549_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0092-8674(00)80620-0","volume":"101","author":"PD Zamore","year":"2000","unstructured":"Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell. 2000;101:25\u201333.","journal-title":"Cell"},{"key":"549_CR5","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nsmb918","volume":"12","author":"FV Rivas","year":"2005","unstructured":"Rivas FV, Tolia NH, Song JJ, Aragon JP, Liu J, Hannon GJ, et al. Purified Argonaute2 and an siRNA form recombinant human RISC. Nat Struct Mol Biol. 2005;12:340\u20139.","journal-title":"Nat Struct Mol Biol"},{"key":"549_CR6","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/nbt.3298","volume":"33","author":"A Wittrup","year":"2015","unstructured":"Wittrup A, Ai A, Liu X, Hamar P, Trifonova R, Charisse K, et al. Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown. Nat Biotechnol. 2015;33:870\u20136.","journal-title":"Nat Biotechnol"},{"key":"549_CR7","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","volume":"18","author":"RL Setten","year":"2019","unstructured":"Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nature Rev Drug Disc. 2019;18:421\u201346.","journal-title":"Nature Rev Drug Disc."},{"key":"549_CR8","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cbpa.2009.08.003","volume":"13","author":"SJ Dixon","year":"2009","unstructured":"Dixon SJ, Stockwell BR. Identifying druggable disease-modifying gene products. Curr Opin Chem Biol. 2009;13:549\u201355.","journal-title":"Curr Opin Chem Biol"},{"key":"549_CR9","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1126\/science.aad8709","volume":"352","author":"BA Sullenger","year":"2016","unstructured":"Sullenger BA, Nair S. From the RNA world to the clinic. Science. 2016;352:1417\u201320.","journal-title":"Science"},{"key":"549_CR10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","volume":"22","author":"L Statello","year":"2021","unstructured":"Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22:96\u2013118.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"549_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/02648725.2018.1471566","volume":"34","author":"A Rafiee","year":"2018","unstructured":"Rafiee A, Riazi-Rad F, Havaskary M, Nuri F. Long noncoding RNAs: regulation, function and cancer. Biotechnol Genet Eng Rev. 2018;34:153\u201380.","journal-title":"Biotechnol Genet Eng Rev"},{"key":"549_CR12","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.3390\/cancers12051122","volume":"12","author":"M Friedrich","year":"2020","unstructured":"Friedrich M, Wiedemann K, Reiche K, Puppel SH, Pfeifer G, Zipfel I, et al. The role of lncRNAs TAPIR-1 and -2 as diagnostic markers and potential therapeutic targets in prostate cancer. Cancers (Basel). 2020;12:1122.","journal-title":"Cancers (Basel)."},{"key":"549_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2174\/187152606776056689","volume":"6","author":"JA Wilson","year":"2006","unstructured":"Wilson JA, Richardson CD. Future promise of siRNA and other nucleic acid based therapeutics for the treatment of chronic HCV. Infect Disord Drug Targets. 2006;6:43\u201356.","journal-title":"Infect Disord Drug Targets"},{"key":"549_CR14","doi-asserted-by":"publisher","first-page":"8800","DOI":"10.1073\/pnas.0912186107","volume":"107","author":"J DeVincenzo","year":"2010","unstructured":"DeVincenzo J, Lambkin-Williams R, Wilkinson T, Cehelsky J, Nochur S, Walsh E, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A. 2010;107:8800\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"549_CR15","doi-asserted-by":"publisher","first-page":"8682","DOI":"10.1073\/pnas.0402630101","volume":"101","author":"SM Tompkins","year":"2004","unstructured":"Tompkins SM, Lo CY, Tumpey TM, Epstein SL. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci U S A. 2004;101:8682\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"549_CR16","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/nm1280","volume":"11","author":"BJ Li","year":"2005","unstructured":"Li BJ, Tang Q, Cheng D, Qin C, Xie FY, Wei Q, et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med. 2005;11:944\u201351.","journal-title":"Nat Med"},{"key":"549_CR17","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1111\/all.14850","volume":"76","author":"M Khaitov","year":"2021","unstructured":"Khaitov M, Nikonova A, Shilovskiy I, Kozhikhova K, Kofiadi I, Vishnyakova L, et al. Silencing of SARS-CoV-2 with modified siRNA-peptide dendrimer formulation. Allergy. 2021;76:2840\u201354.","journal-title":"Allergy"},{"key":"549_CR18","doi-asserted-by":"publisher","first-page":"2219-26","DOI":"10.1016\/j.ymthe.2021.05.004","volume":"29","author":"A Idris","year":"2021","unstructured":"Idris A, Davis A, Supramaniam A, Acharya D, Kelly G, Tayyar Y, et al. A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19. Mol Ther. 2021;29:2219\u201326.","journal-title":"Mol Ther."},{"key":"549_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/cbdd.13978","volume":"99","author":"H Saify Nabiabad","year":"2022","unstructured":"Saify Nabiabad H, Amini M, Demirdas S. Specific delivering of RNAi using Spike\u2019s aptamer-functionalized lipid nanoparticles for targeting SARS-CoV-2: a strong anti-Covid drug in a clinical case study. Chem Biol Drug Des. 2022;99:233\u201346.","journal-title":"Chem Biol Drug Des"},{"issue":"4","key":"549_CR20","doi-asserted-by":"publisher","first-page":"e15298","DOI":"10.15252\/emmm.202115298","volume":"14","author":"YC Chang","year":"2022","unstructured":"Chang YC, Yang CF, Chen YF, Yang CC, Chou YL, Chou HW, et al. A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant. EMBO Mol Med. 2022;14(4):e15298.","journal-title":"EMBO Mol Med"},{"key":"549_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.801870","volume":"10","author":"M Friedrich","year":"2022","unstructured":"Friedrich M, Pfeifer G, Binder S, Aigner A, Vollmer Barbosa P, Makert GR, et al. Selection and validation of siRNAs preventing uptake and replication of SARS-CoV-2. Front Bioeng Biotechnol. 2022;10: 801870.","journal-title":"Front Bioeng Biotechnol."},{"key":"549_CR22","doi-asserted-by":"publisher","first-page":"6877","DOI":"10.1093\/emboj\/20.23.6877","volume":"20","author":"SM Elbashir","year":"2001","unstructured":"Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J. 2001;20:6877\u201388.","journal-title":"EMBO J"},{"key":"549_CR23","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.1073\/pnas.092143499","volume":"99","author":"JY Yu","year":"2002","unstructured":"Yu JY, DeRuiter SL, Turner DL. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci U S A. 2002;99:6047\u201352.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"549_CR24","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nbt0502-500","volume":"20","author":"NS Lee","year":"2002","unstructured":"Lee NS, Dohjima T, Bauer G, Li H, Li MJ, Ehsani A, et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol. 2002;20:500\u20135.","journal-title":"Nat Biotechnol"},{"key":"549_CR25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/cgt.2016.4","volume":"23","author":"E Fakhr","year":"2016","unstructured":"Fakhr E, Zare F, Teimoori-Toolabi L. Precise and efficient siRNA design: a key point in competent gene silencing. Cancer Gene Ther. 2016;23:73\u201382.","journal-title":"Cancer Gene Ther"},{"key":"549_CR26","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/nbt1161","volume":"23","author":"JT Marques","year":"2005","unstructured":"Marques JT, Williams BR. Activation of the mammalian immune system by siRNAs. Nat Biotechnol. 2005;23:1399\u2013405.","journal-title":"Nat Biotechnol"},{"key":"549_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","volume":"5","author":"B Hu","year":"2020","unstructured":"Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, Liang XJ. Therapeutic siRNA: state of the art. Signal Transduct Target Ther. 2020;5:101.","journal-title":"Signal Transduct Target Ther"},{"key":"549_CR28","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41577-020-0288-3","volume":"20","author":"J Rehwinkel","year":"2020","unstructured":"Rehwinkel J, Gack MU. RIG-I-like receptors: their regulation and roles in RNA sensing. Nat Rev Immunol. 2020;20:537\u201351.","journal-title":"Nat Rev Immunol"},{"key":"549_CR29","doi-asserted-by":"publisher","first-page":"4900","DOI":"10.1093\/nar\/gkl464","volume":"34","author":"S Puthenveetil","year":"2006","unstructured":"Puthenveetil S, Whitby L, Ren J, Kelnar K, Krebs JF, Beal PA. Controlling activation of the RNA-dependent protein kinase by siRNAs using site-specific chemical modification. Nucleic Acids Res. 2006;34:4900\u201311.","journal-title":"Nucleic Acids Res"},{"key":"549_CR30","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.jmb.2013.11.024","volume":"426","author":"SN Lester","year":"2014","unstructured":"Lester SN, Li K. Toll-like receptors in antiviral innate immunity. J Mol Biol. 2014;426:1246\u201364.","journal-title":"J Mol Biol"},{"key":"549_CR31","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.bbrc.2004.02.157","volume":"316","author":"M Amarzguioui","year":"2004","unstructured":"Amarzguioui M, Prydz H. An algorithm for selection of functional siRNA sequences. Biochem Biophys Res Commun. 2004;316:1050\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"549_CR32","doi-asserted-by":"publisher","first-page":"7100","DOI":"10.1093\/nar\/gkn902","volume":"36","author":"K Ui-Tei","year":"2008","unstructured":"Ui-Tei K, Naito Y, Nishi K, Juni A, Saigo K. Thermodynamic stability and Watson-Crick base pairing in the seed duplex are major determinants of the efficiency of the siRNA-based off-target effect. Nucleic Acids Res. 2008;36:7100\u20139.","journal-title":"Nucleic Acids Res"},{"key":"549_CR33","doi-asserted-by":"publisher","first-page":"603","DOI":"10.15171\/apb.2017.072","volume":"7","author":"F Safari","year":"2017","unstructured":"Safari F, Rahmani Barouji S, Tamaddon AM. Strategies for improving siRNA-induced gene silencing efficiency. Adv Pharm Bull. 2017;7:603\u20139.","journal-title":"Adv Pharm Bull."},{"key":"549_CR34","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1038\/nprot.2007.278","volume":"2","author":"A Birmingham","year":"2007","unstructured":"Birmingham A, Anderson E, Sullivan K, Reynolds A, Boese Q, Leake D, et al. A protocol for designing siRNAs with high functionality and specificity. Nat Protoc. 2007;2:2068\u201378.","journal-title":"Nat Protoc"},{"key":"549_CR35","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1261\/rna.7275905","volume":"11","author":"B Jagla","year":"2005","unstructured":"Jagla B, Aulner N, Kelly PD, Song D, Volchuk A, Zatorski A, et al. Sequence characteristics of functional siRNAs. RNA. 2005;11:864\u201372.","journal-title":"RNA"},{"key":"549_CR36","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/nbt936","volume":"22","author":"A Reynolds","year":"2004","unstructured":"Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol. 2004;22:326\u201330.","journal-title":"Nat Biotechnol"},{"key":"549_CR37","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/978-1-62703-709-9_22","volume":"1097","author":"H Tafer","year":"2014","unstructured":"Tafer H. Bioinformatics of siRNA design. Methods Mol Biol. 2014;1097:477\u201390.","journal-title":"Methods Mol Biol"},{"key":"549_CR38","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0092-8674(03)00801-8","volume":"115","author":"A Khvorova","year":"2003","unstructured":"Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell. 2003;115:209\u201316.","journal-title":"Cell"},{"key":"549_CR39","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1021\/bi00118a028","volume":"31","author":"CC Hardin","year":"1992","unstructured":"Hardin CC, Watson T, Corregan M, Bailey C. Cation-dependent transition between the quadruplex and Watson-Crick hairpin forms of d(CGCG3GCG). Biochemistry. 1992;31:833\u201341.","journal-title":"Biochemistry"},{"key":"549_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2015.23","volume":"4","author":"JK Lam","year":"2015","unstructured":"Lam JK, Chow MY, Zhang Y, Leung SW. siRNA versus miRNA as therapeutics for gene silencing. Mol Ther Nucleic Acids. 2015;4: e252.","journal-title":"Mol Ther Nucleic Acids."},{"key":"549_CR41","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1038\/s41598-022-09051-w","volume":"12","author":"M Patel","year":"2022","unstructured":"Patel M, Bartom ET, Paudel B, Kocherginsky M, O\u2019Shea KL, Murmann AE, et al. Identification of the toxic 6mer seed consensus for human cancer cells. Sci Rep. 2022;12:5130.","journal-title":"Sci Rep"},{"key":"549_CR42","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1261\/rna.28106","volume":"12","author":"Y Fedorov","year":"2006","unstructured":"Fedorov Y, Anderson EM, Birmingham A, Reynolds A, Karpilow J, Robinson K, et al. Off-target effects by siRNA can induce toxic phenotype. RNA. 2006;12:1188\u201396.","journal-title":"RNA"},{"key":"549_CR43","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1093\/nar\/15.11.4403","volume":"15","author":"S Shibahara","year":"1987","unstructured":"Shibahara S, Mukai S, Nishihara T, Inoue H, Ohtsuka E, Morisawa H. Site-directed cleavage of RNA. Nucleic Acids Res. 1987;15:4403\u201315.","journal-title":"Nucleic Acids Res"},{"key":"549_CR44","doi-asserted-by":"publisher","first-page":"W104","DOI":"10.1093\/nar\/gkn250","volume":"36","author":"ZJ Lu","year":"2008","unstructured":"Lu ZJ, Mathews DH. OligoWalk: an online siRNA design tool utilizing hybridization thermodynamics. Nucleic Acids Res. 2008;36:W104\u20138.","journal-title":"Nucleic Acids Res"},{"key":"549_CR45","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/nar\/gkm920","volume":"36","author":"ZJ Lu","year":"2008","unstructured":"Lu ZJ, Mathews DH. Efficient siRNA selection using hybridization thermodynamics. Nucleic Acids Res. 2008;36:640\u20137.","journal-title":"Nucleic Acids Res"},{"key":"549_CR46","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/nbt1404","volume":"26","author":"H Tafer","year":"2008","unstructured":"Tafer H, Ameres SL, Obernosterer G, Gebeshuber CA, Schroeder R, Martinez J, et al. The impact of target site accessibility on the design of effective siRNAs. Nat Biotechnol. 2008;26:578\u201383.","journal-title":"Nat Biotechnol"},{"key":"549_CR47","doi-asserted-by":"publisher","first-page":"W135","DOI":"10.1093\/nar\/gkh449","volume":"32","author":"Y Ding","year":"2004","unstructured":"Ding Y, Chan CY, Lawrence CE. Sfold web server for statistical folding and rational design of nucleic acids. Nucleic Acids Res. 2004;32:W135\u201341.","journal-title":"Nucleic Acids Res"},{"key":"549_CR48","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1261\/rna.546207","volume":"13","author":"Y Shao","year":"2007","unstructured":"Shao Y, Chan CY, Maliyekkel A, Lawrence CE, Roninson IB, Ding Y. Effect of target secondary structure on RNAi efficiency. RNA. 2007;13:1631\u201340.","journal-title":"RNA"},{"key":"549_CR49","doi-asserted-by":"publisher","first-page":"D10","DOI":"10.1093\/nar\/gkaa892","volume":"49","author":"EW Sayers","year":"2021","unstructured":"Sayers EW, Beck J, Bolton EE, Bourexis D, Brister JR, Canese K, et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 2021;49:D10\u20137.","journal-title":"Nucleic Acids Res"},{"key":"549_CR50","doi-asserted-by":"publisher","first-page":"D884","DOI":"10.1093\/nar\/gkaa942","volume":"49","author":"KL Howe","year":"2021","unstructured":"Howe KL, Achuthan P, Allen J, Allen J, Alvarez-Jarreta J, Amode MR, et al. Ensembl 2021. Nucleic Acids Res. 2021;49:D884\u201391.","journal-title":"Nucleic Acids Res"},{"key":"549_CR51","doi-asserted-by":"publisher","first-page":"D1115","DOI":"10.1093\/nar\/gkab959","volume":"50","author":"BT Lee","year":"2022","unstructured":"Lee BT, Barber GP, Benet-Pag\u00e8s A, Casper J, Clawson H, Diekhans M, et al. The UCSC Genome Browser database: 2022 update. Nucleic Acids Res. 2022;50:D1115\u201322.","journal-title":"Nucleic Acids Res"},{"key":"549_CR52","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.drudis.2008.05.007","volume":"13","author":"JK Watts","year":"2008","unstructured":"Watts JK, Deleavey GF, Damha MJ. Chemically modified siRNA: tools and applications. Drug Discov Today. 2008;13:842\u201355.","journal-title":"Drug Discov Today"},{"key":"549_CR53","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nbt.3765","volume":"35","author":"A Khvorova","year":"2017","unstructured":"Khvorova A, Watts JK. The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol. 2017;35:238\u201348.","journal-title":"Nat Biotechnol"},{"key":"549_CR54","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/nar\/gkx1239","volume":"46","author":"X Shen","year":"2018","unstructured":"Shen X, Corey DR. Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res. 2018;46:1584\u2013600.","journal-title":"Nucleic Acids Res"},{"key":"549_CR55","doi-asserted-by":"publisher","first-page":"6131","DOI":"10.1093\/nar\/15.15.6131","volume":"15","author":"H Inoue","year":"1987","unstructured":"Inoue H, Hayase Y, Imura A, Iwai S, Miura K, Ohtsuka E. Synthesis and hybridization studies on two complementary nona(2\u2032-O-methyl)ribonucleotides. Nucleic Acids Res. 1987;15:6131\u201348.","journal-title":"Nucleic Acids Res"},{"key":"549_CR56","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1093\/nar\/gkl033","volume":"34","author":"T Dowler","year":"2006","unstructured":"Dowler T, Bergeron D, Tedeschi AL, Paquet L, Ferrari N, Damha MJ. Improvements in siRNA properties mediated by 2\u2032-deoxy-2\u2032-fluoro-beta-D-arabinonucleic acid (FANA). Nucleic Acids Res. 2006;34:1669\u201375.","journal-title":"Nucleic Acids Res"},{"key":"549_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2011.4","volume":"1","author":"DM Kenski","year":"2012","unstructured":"Kenski DM, Butora G, Willingham AT, Cooper AJ, Fu W, Qi N, et al. siRNA-optimized modifications for enhanced in vivo activity. Mol Ther Nucleic Acids. 2012;1: e5.","journal-title":"Mol Ther Nucleic Acids."},{"key":"549_CR58","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ddtec.2005.08.012","volume":"2","author":"S Kauppinen","year":"2005","unstructured":"Kauppinen S, Vester B, Wengel J. Locked nucleic acid (LNA): high affinity targeting of RNA for diagnostics and therapeutics. Drug Discov Today Technol. 2005;2:287\u201390.","journal-title":"Drug Discov Today Technol"},{"key":"549_CR59","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","volume":"70","author":"CF Bennett","year":"2019","unstructured":"Bennett CF. Therapeutic antisense oligonucleotides are coming of age. Annu Rev Med. 2019;70:307\u201321.","journal-title":"Annu Rev Med"},{"key":"549_CR60","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1093\/nar\/gkaa299","volume":"48","author":"ST Crooke","year":"2020","unstructured":"Crooke ST, Vickers TA, Liang XH. Phosphorothioate modified oligonucleotide-protein interactions. Nucleic Acids Res. 2020;48:5235\u201353.","journal-title":"Nucleic Acids Res"},{"key":"549_CR61","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/mt.2010.266","volume":"19","author":"Y Huang","year":"2011","unstructured":"Huang Y, Hong J, Zheng S, Ding Y, Guo S, Zhang H, Zhang X, Du Q, Liang Z. Elimination pathways of systemically delivered siRNA. Mol Ther. 2011;19:381\u20135.","journal-title":"Mol Ther"},{"key":"549_CR62","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1089\/ard.1995.5.213","volume":"5","author":"DA Geselowitz","year":"1995","unstructured":"Geselowitz DA, Neckers LM. Bovine serum albumin is a major oligonucleotide-binding protein found on the surface of cultured cells. Antisense Res Dev. 1995;5:213\u20137.","journal-title":"Antisense Res Dev"},{"key":"549_CR63","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41587-019-0106-2","volume":"37","author":"W Shen","year":"2019","unstructured":"Shen W, De Hoyos CL, Migawa MT, Vickers TA, Sun H, Low A, Bell TA 3rd, et al. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. Nat Biotechnol. 2019;37:640\u201350.","journal-title":"Nat Biotechnol"},{"key":"549_CR64","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.1093\/nar\/gkz247","volume":"47","author":"MT Migawa","year":"2019","unstructured":"Migawa MT, Shen W, Wan WB, Vasquez G, Oestergaard ME, Low A, et al. Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins. Nucleic Acids Res. 2019;47:5465\u201379.","journal-title":"Nucleic Acids Res"},{"key":"549_CR65","doi-asserted-by":"publisher","first-page":"7581","DOI":"10.1093\/nar\/gkx507","volume":"45","author":"RA Haraszti","year":"2017","unstructured":"Haraszti RA, Roux L, Coles AH, Turanov AA, Alterman JF, Echeverria D, et al. 5\u2032-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo. Nucleic Acids Res. 2017;45:7581\u201392.","journal-title":"Nucleic Acids Res"},{"key":"549_CR66","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/cbic.201600130","volume":"17","author":"R Parmar","year":"2016","unstructured":"Parmar R, Willoughby JL, Liu J, Foster DJ, Brigham B, Theile CS, et al. 5\u2032-(E)-Vinylphosphonate: a stable phosphate mimic can improve the RNAi activity of siRNA-GalNAc conjugates. ChemBioChem. 2016;17:985\u20139.","journal-title":"ChemBioChem"},{"key":"549_CR67","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.1093\/nar\/gkw1171","volume":"45","author":"E Elkayam","year":"2017","unstructured":"Elkayam E, Parmar R, Brown CR, Willoughby JL, Theile CS, Manoharan M, Joshua-Tor L. siRNA carrying an (E)-vinylphosphonate moiety at the 5\u0384 end of the guide strand augments gene silencing by enhanced binding to human Argonaute-2. Nucleic Acids Res. 2017;45:5008.","journal-title":"Nucleic Acids Res"},{"key":"549_CR68","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/cbic.201402551","volume":"16","author":"RA Valenzuela","year":"2015","unstructured":"Valenzuela RA, Suter SR, Ball-Jones AA, Ibarra-Soza JM, Zheng Y, Beal PA. Base modification strategies to modulate immune stimulation by an siRNA. ChemBioChem. 2015;16:262\u20137.","journal-title":"ChemBioChem"},{"key":"549_CR69","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1021\/cb500270x","volume":"9","author":"KJ Phelps","year":"2014","unstructured":"Phelps KJ, Ibarra-Soza JM, Tran K, Fisher AJ, Beal PA. Click modification of RNA at adenosine: structure and reactivity of 7-ethynyl- and 7-triazolyl-8-aza-7-deazaadenosine in RNA. ACS Chem Biol. 2014;9:1780\u20137.","journal-title":"ACS Chem Biol"},{"key":"549_CR70","doi-asserted-by":"publisher","first-page":"4650","DOI":"10.1093\/nar\/gkt120","volume":"41","author":"SY Wu","year":"2013","unstructured":"Wu SY, Chen TM, Gmeiner WH, Chu E, Schmitz JC. Development of modified siRNA molecules incorporating 5-fluoro-2\u2032-deoxyuridine residues to enhance cytotoxicity. Nucleic Acids Res. 2013;41:4650\u20139.","journal-title":"Nucleic Acids Res"},{"key":"549_CR71","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.ekir.2017.03.016","volume":"2","author":"S Demirjian","year":"2017","unstructured":"Demirjian S, Ailawadi G, Polinsky M, Bitran D, Silberman S, Shernan SK, et al. Safety and tolerability study of an intravenously administered small interfering ribonucleic acid (siRNA) post on-pump cardiothoracic surgery in patients at risk of acute kidney injury. Kidney Int Rep. 2017;2:836\u201343.","journal-title":"Kidney Int Rep."},{"key":"549_CR72","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1089\/nat.2014.0489","volume":"24","author":"EC Solano","year":"2014","unstructured":"Solano EC, Kornbrust DJ, Beaudry A, Foy JW, Schneider DJ, Thompson JD. Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection. Nucleic Acid Ther. 2014;24:258\u201366.","journal-title":"Nucleic Acid Ther"},{"key":"549_CR73","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11\u201321.","journal-title":"N Engl J Med"},{"key":"549_CR74","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMoa1807838","volume":"380","author":"E Sardh","year":"2019","unstructured":"Sardh E, Harper P, Balwani M, Stein P, Rees D, Bissell DM, et al. Phase 1 trial of an RNA interference therapy for acute intermittent porphyria. N Engl J Med. 2019;380:549\u201358.","journal-title":"N Engl J Med"},{"key":"549_CR75","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","volume":"382","author":"M Balwani","year":"2020","unstructured":"Balwani M, Sardh E, Ventura P, Peir\u00f3 PA, Rees DC, St\u00f6lzel U, et al. Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria. N Engl J Med. 2020;382:2289\u2013301.","journal-title":"N Engl J Med"},{"key":"549_CR76","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609243","volume":"376","author":"K Fitzgerald","year":"2017","unstructured":"Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376:41\u201351.","journal-title":"N Engl J Med"},{"key":"549_CR77","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1681\/ASN.2016030338","volume":"28","author":"A Liebow","year":"2017","unstructured":"Liebow A, Li X, Racie T, Hettinger J, Bettencourt BR, Najafian N, et al. An investigational RNAi therapeutic targeting glycolate oxidase reduces oxalate production in models of primary hyperoxaluria. J Am Soc Nephrol. 2017;28:494\u2013503.","journal-title":"J Am Soc Nephrol"},{"key":"549_CR78","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.135348","volume":"5","author":"CI Wooddell","year":"2020","unstructured":"Wooddell CI, Blomenkamp K, Peterson RM, Subbotin VM, Schwabe C, Hamilton J, et al. Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease. JCI Insight. 2020;5: e135348.","journal-title":"JCI Insight."},{"key":"549_CR79","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1194\/jlr.M089508","volume":"60","author":"AA Butler","year":"2019","unstructured":"Butler AA, Price CA, Graham JL, Stanhope KL, King S, Hung YH, et al. Fructose-induced hypertriglyceridemia in rhesus macaques is attenuated with fish oil or ApoC3 RNA interference. J Lipid Res. 2019;60:805\u201318.","journal-title":"J Lipid Res"},{"key":"549_CR80","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.omtn.2018.02.005","volume":"11","author":"H Javanbakht","year":"2018","unstructured":"Javanbakht H, Mueller H, Walther J, Zhou X, Lopez A, Pattupara T, et al. Liver-targeted anti-HBV single-stranded oligonucleotides with locked nucleic acid potently reduce HBV gene expression in vivo. Mol Ther Nucleic Acids. 2018;11:441\u201354.","journal-title":"Mol Ther Nucleic Acids."},{"key":"549_CR81","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/978-1-60761-588-0_5","volume":"623","author":"YJ Kim","year":"2010","unstructured":"Kim YJ. Computational siRNA design considering alternative splicing. Methods Mol Biol. 2010;623:81\u201392.","journal-title":"Methods Mol Biol"},{"key":"549_CR82","doi-asserted-by":"publisher","first-page":"406","DOI":"10.4161\/rna.6.4.9218","volume":"6","author":"G Sun","year":"2009","unstructured":"Sun G, Rossi JJ. Problems associated with reporter assays in RNAi studies. RNA Biol. 2009;6:406\u201311.","journal-title":"RNA Biol"},{"key":"549_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114236","volume":"184","author":"P Vervaeke","year":"2022","unstructured":"Vervaeke P, Borgos SE, Sanders NN, Combes F. Regulatory guidelines and preclinical tools to study the biodistribution of RNA therapeutics. Adv Drug Deliv Rev. 2022;184: 114236.","journal-title":"Adv Drug Deliv Rev"},{"key":"549_CR84","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/mt.2009.91","volume":"17","author":"S Gao","year":"2009","unstructured":"Gao S, Dagnaes-Hansen F, Nielsen EJ, Wengel J, Besenbacher F, Howard KA, et al. The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther. 2009;17:1225\u201333.","journal-title":"Mol Ther"},{"key":"549_CR85","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0065-2423(10)50006-4","volume":"50","author":"M Rajappa","year":"2010","unstructured":"Rajappa M, Saxena P, Kaur J. Ocular angiogenesis: mechanisms and recent advances in therapy. Adv Clin Chem. 2010;50:103\u201321.","journal-title":"Adv Clin Chem"},{"key":"549_CR86","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nmat3765","volume":"12","author":"R Kanasty","year":"2013","unstructured":"Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mater. 2013;12:967\u201377.","journal-title":"Nat Mater"},{"key":"549_CR87","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jconrel.2014.12.030","volume":"200","author":"A Wicki","year":"2015","unstructured":"Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release. 2015;200:138\u201357.","journal-title":"J Control Release"},{"key":"549_CR88","doi-asserted-by":"publisher","first-page":"e1903637","DOI":"10.1002\/adma.201903637","volume":"31","author":"B Kim","year":"2019","unstructured":"Kim B, Park JH, Sailor MJ. Rekindling RNAi therapy: materials design requirements for in vivo siRNA delivery. Adv Mater. 2019;31:e1903637.","journal-title":"Adv Mater"},{"key":"549_CR89","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.2217\/nnm-2019-0321","volume":"14","author":"A Aigner","year":"2019","unstructured":"Aigner A. Perspectives, issues and solutions in RNAi therapy: the expected and the less expected. Nanomedicine (Lond). 2019;14:2777\u201382.","journal-title":"Nanomedicine (Lond)"},{"key":"549_CR90","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.addr.2019.05.004","volume":"144","author":"Y Dong","year":"2019","unstructured":"Dong Y, Siegwart DJ, Anderson DG. Strategies, design, and chemistry in siRNA delivery systems. Adv Drug Deliv Rev. 2019;144:133\u201347.","journal-title":"Adv Drug Deliv Rev"},{"key":"549_CR91","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nbt.3802","volume":"35","author":"SF Dowdy","year":"2017","unstructured":"Dowdy SF. Overcoming cellular barriers for RNA therapeutics. Nat Biotechnol. 2017;35:222\u20139.","journal-title":"Nat Biotechnol"},{"key":"549_CR92","doi-asserted-by":"publisher","first-page":"5216","DOI":"10.1016\/j.bmc.2008.03.017","volume":"16","author":"O Khorev","year":"2008","unstructured":"Khorev O, Stokmaier D, Schwardt O, Cutting B, Ernst B. Trivalent, Gal\/GalNAc-containing ligands designed for the asialoglycoprotein receptor. Bioorg Med Chem. 2008;16:5216\u201331.","journal-title":"Bioorg Med Chem"},{"key":"549_CR93","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/cbic.201500023","volume":"16","author":"KG Rajeev","year":"2015","unstructured":"Rajeev KG, Nair JK, Jayaraman M, Charisse K, Taneja N, O\u2019Shea J, et al. Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo. ChemBioChem. 2015;16:903\u20138.","journal-title":"ChemBioChem"},{"key":"549_CR94","doi-asserted-by":"publisher","first-page":"8796","DOI":"10.1093\/nar\/gku531","volume":"42","author":"TP Prakash","year":"2014","unstructured":"Prakash TP, Graham MJ, Yu J, Carty R, Low A, Chappell A, et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 2014;42:8796\u2013807.","journal-title":"Nucleic Acids Res"},{"key":"549_CR95","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/nat.2018.0736","volume":"28","author":"AD Springer","year":"2018","unstructured":"Springer AD, Dowdy SF. GalNAc-siRNA Conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid Ther. 2018;28:109\u201318.","journal-title":"Nucleic Acid Ther"},{"key":"549_CR96","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nbt.1602","volume":"28","author":"SC Semple","year":"2010","unstructured":"Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010;28:172\u20136.","journal-title":"Nat Biotechnol"},{"key":"549_CR97","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jconrel.2012.09.009","volume":"163","author":"Y Sato","year":"2012","unstructured":"Sato Y, Hatakeyama H, Sakurai Y, Hyodo M, Akita H, Harashima H. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo. J Control Release. 2012;163:267\u201376.","journal-title":"J Control Release"},{"key":"549_CR98","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nbt1402","volume":"26","author":"A Akinc","year":"2008","unstructured":"Akinc A, Zumbuehl A, Goldberg M, Leshchiner ES, Busini V, Hossain N, et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol. 2008;26:561\u20139.","journal-title":"Nat Biotechnol"},{"key":"549_CR99","doi-asserted-by":"publisher","first-page":"8529","DOI":"10.1002\/anie.201203263","volume":"51","author":"M Jayaraman","year":"2012","unstructured":"Jayaraman M, Ansell SM, Mui BL, Tam YK, Chen J, Du X, et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl. 2012;51:8529\u201333.","journal-title":"Angew Chem Int Ed Engl"},{"key":"549_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2013.66","volume":"2","author":"BL Mui","year":"2013","unstructured":"Mui BL, Tam YK, Jayaraman M, Ansell SM, Du X, Tam YY, et al. Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles. Mol Ther Nucleic Acids. 2013;2: e139.","journal-title":"Mol Ther Nucleic Acids."},{"key":"549_CR101","doi-asserted-by":"publisher","first-page":"6922","DOI":"10.1021\/nn301922x","volume":"6","author":"KA Whitehead","year":"2012","unstructured":"Whitehead KA, Matthews J, Chang PH, Niroui F, Dorkin JR, Severgnini M, et al. In vitro-in vivo translation of lipid nanoparticles for hepatocellular siRNA delivery. ACS Nano. 2012;6:6922\u20139.","journal-title":"ACS Nano"},{"key":"549_CR102","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.3390\/molecules22081356","volume":"22","author":"I Cedillo","year":"2017","unstructured":"Cedillo I, Chreng D, Engle E, Chen L, McPherson AK, Rodriguez AA. Synthesis of 5\u2032-GalNAc-conjugated oligonucleotides: a comparison of solid and solution-phase conjugation strategies. Molecules. 2017;22:1356.","journal-title":"Molecules"},{"key":"549_CR103","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/ph12020052","volume":"12","author":"D Al Shaer","year":"2019","unstructured":"Al Shaer D, Al Musaimi O, Albericio F, de la Torre BG. 2018 FDA tides harvest. Pharmaceuticals (Basel). 2019;12:52.","journal-title":"Pharmaceuticals (Basel)"},{"key":"549_CR104","first-page":"570","volume":"14","author":"H Wood","year":"2018","unstructured":"Wood H. FDA approves patisiran to treat hereditary transthyretin amyloidosis. Nat Rev Neurol. 2018;14:570.","journal-title":"Nat Rev Neurol"},{"key":"549_CR105","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","volume":"78","author":"SM Hoy","year":"2018","unstructured":"Hoy SM. Patisiran: first global approval. Drugs. 2018;78:1625\u201331.","journal-title":"Drugs"},{"key":"549_CR106","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/jcph.1553","volume":"60","author":"X Zhang","year":"2019","unstructured":"Zhang X, Goel V, Robbie GJ. Pharmacokinetics of patisiran, the first approved RNA interference therapy in patients with hereditary transthyretin-mediated amyloidosis. J Clin Pharmacol. 2019;60:573\u201385.","journal-title":"J Clin Pharmacol"},{"key":"549_CR107","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1208760","volume":"369","author":"T Coelho","year":"2013","unstructured":"Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369:819\u201329.","journal-title":"N Engl J Med"},{"key":"549_CR108","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","volume":"139","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, Adams D, Kristen A, Grogan M, Gonz\u00e1lez-Duarte A, Maurer MS, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation. 2019;139:431\u201343.","journal-title":"Circulation"},{"key":"549_CR109","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1111\/ajt.17009","volume":"22","author":"HH Schmidt","year":"2022","unstructured":"Schmidt HH, Wixner J, Plant\u00e9-Bordeneuve V, Mu\u00f1oz-Beamud F, Llad\u00f3 L, Gillmore JD, et al. Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation. Am J Transplant. 2022;22:1646\u201357.","journal-title":"Am J Transplant"},{"key":"549_CR110","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","volume":"80","author":"LJ Scott","year":"2020","unstructured":"Scott LJ. Givosiran: first approval. Drugs. 2020;80:335\u20139.","journal-title":"Drugs"},{"key":"549_CR111","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/ph13030040","volume":"13","author":"D Al Shaer","year":"2020","unstructured":"Al Shaer D, Al Musaimi O, Albericio F, de la Torre BG. 2019 FDA TIDES (peptides and oligonucleotides) harvest. Pharmaceuticals (Basel). 2020;13:40.","journal-title":"Pharmaceuticals (Basel)"},{"key":"549_CR112","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/hep4.1297","volume":"3","author":"B Wang","year":"2019","unstructured":"Wang B, Rudnick S, Cengia B, Bonkovsky HL. Acute hepatic porphyrias: review and recent progress. Hepatol Commun. 2019;3:193\u2013206.","journal-title":"Hepatol Commun"},{"key":"549_CR113","doi-asserted-by":"publisher","first-page":"7777","DOI":"10.1073\/pnas.1406228111","volume":"111","author":"M Yasuda","year":"2014","unstructured":"Yasuda M, Gan L, Chen B, Kadirvel S, Yu C, Phillips JD, et al. RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice. Proc Natl Acad Sci U S A. 2014;111:7777\u201382.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"549_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2015.36","volume":"4","author":"A Chan","year":"2015","unstructured":"Chan A, Liebow A, Yasuda M, Gan L, Racie T, Maier M, et al. Preclinical development of a subcutaneous ALAS1 RNAi therapeutic for treatment of hepatic porphyrias using circulating RNA quantification. Mol Ther Nucleic Acids. 2015;4: e263.","journal-title":"Mol Ther Nucleic Acids."},{"key":"549_CR115","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/cpt.1802","volume":"108","author":"S Agarwal","year":"2020","unstructured":"Agarwal S, Simon AR, Goel V, Habtemariam BA, Clausen VA, Kim JB, et al. Pharmacokinetics and pharmacodynamics of the small interfering ribonucleic acid, givosiran, in patients with acute hepatic porphyria. Clin Pharmacol Ther. 2020;108:63\u201372.","journal-title":"Clin Pharmacol Ther"},{"key":"549_CR116","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s40265-021-01511-3","volume":"81","author":"YY Syed","year":"2021","unstructured":"Syed YY. Givosiran: a review in acute hepatic porphyria. Drugs. 2021;81:841\u20138.","journal-title":"Drugs"},{"key":"549_CR117","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/liv.15090","volume":"42","author":"P Ventura","year":"2021","unstructured":"Ventura P, Bonkovsky HL, Gouya L, Aguilera-Peir\u00f3 P, Montgomery Bissell D, Stein PE, et al. Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study. Liver Int. 2021;42:161\u201372.","journal-title":"Liver Int"},{"key":"549_CR118","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jacl.2019.11.001","volume":"14","author":"K Dyrbu\u015b","year":"2020","unstructured":"Dyrbu\u015b K, G\u0105sior M, Penson P, Ray KK, Banach M. Inclisiran: new hope in the management of lipid disorders? J Clin Lipidol. 2020;14:16\u201327.","journal-title":"J Clin Lipidol"},{"key":"549_CR119","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382:1520\u201330.","journal-title":"N Engl J Med"},{"key":"549_CR120","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382:1507\u201319.","journal-title":"N Engl J Med"},{"key":"549_CR121","volume":"368","author":"AN Bamji","year":"2020","unstructured":"Bamji AN. Do PCSK9 inhibitors do anything more than reduce LDL cholesterol? BMJ Clin Res. 2020;368: m1159.","journal-title":"BMJ Clin Res."},{"key":"549_CR122","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/j.ymthe.2018.05.016","volume":"26","author":"C Lai","year":"2018","unstructured":"Lai C, Pursell N, Gierut J, Saxena U, Zhou W, Dills M, et al. Specific inhibition of hepatic lactate dehydrogenase reduces oxalate production in mouse models of primary hyperoxaluria. Mol Ther. 2018;26:1983\u201395.","journal-title":"Mol Ther"},{"key":"549_CR123","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/mt.2016.4","volume":"24","author":"C Dutta","year":"2016","unstructured":"Dutta C, Avitahl-Curtis N, Pursell N, Larsson Cohen M, Holmes B, Diwanji R, et al. Inhibition of glycolate oxidase with Dicer-substrate siRNA reduces calcium oxalate deposition in a mouse model of primary hyperoxaluria type 1. Mol Ther. 2016;24:770\u20138.","journal-title":"Mol Ther"},{"key":"549_CR124","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40265-020-01463-0","volume":"81","author":"LJ Scott","year":"2021","unstructured":"Scott LJ. Keam SJ. Lumasiran: first approval. Drugs. 2021;81:277\u201382.","journal-title":"Drugs"},{"key":"549_CR125","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","volume":"384","author":"SF Garrelfs","year":"2021","unstructured":"Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O\u2019Riordan WD, Cochat P, et al. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med. 2021;384:1216\u201326.","journal-title":"N Engl J Med"},{"key":"549_CR126","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.2215\/CJN.14730920","volume":"16","author":"Y Frishberg","year":"2021","unstructured":"Frishberg Y, Desch\u00eanes G, Groothoff JW, Hulton SA, Magen D, Harambat J, et al. Phase 1\/2 study of lumasiran for treatment of primary hyperoxaluria type 1: a placebo-controlled randomized clinical trial. Clin J Am Soc Nephrol. 2021;16:1025\u201336.","journal-title":"Clin J Am Soc Nephrol"},{"key":"549_CR127","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ymthe.2017.12.021","volume":"26","author":"DJ Foster","year":"2018","unstructured":"Foster DJ, Brown CR, Shaikh S, Trapp C, Schlegel MK, Qian K, et al. Advanced siRNA designs further improve in vivo performance of GalNAc-siRNA conjugates. Mol Ther. 2018;26:708\u201317.","journal-title":"Mol Ther"},{"key":"549_CR128","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1093\/nar\/gkz140","volume":"47","author":"MM Janas","year":"2019","unstructured":"Janas MM, Zlatev I, Liu J, Jiang Y, Barros SA, Sutherland JE, et al. Safety evaluation of 2\u2032-deoxy-2\u2032-fluoro nucleotides in GalNAc-siRNA conjugates. Nucleic Acids Res. 2019;47:3306\u201320.","journal-title":"Nucleic Acids Res"},{"key":"549_CR129","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/cpt.1974","volume":"109","author":"BA Habtemariam","year":"2021","unstructured":"Habtemariam BA, Karsten V, Attarwala H, Goel V, Melch M, Clausen VA, et al. Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects. Clin Pharmacol Ther. 2021;109:372\u201382.","journal-title":"Clin Pharmacol Ther"},{"key":"549_CR130","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.kint.2021.08.015","volume":"101","author":"B Hoppe","year":"2021","unstructured":"Hoppe B, Koch A, Cochat P, Garrelfs SF, Baum MA, Groothoff JW, et al. Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria. Kidney Int. 2021;101:626\u201334.","journal-title":"Kidney Int"},{"key":"549_CR131","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/0009-8981(88)90359-2","volume":"173","author":"T Kanno","year":"1988","unstructured":"Kanno T, Sudo K, Maekawa M, Nishimura Y, Ukita M, Fukutake K. Lactate dehydrogenase M-subunit deficiency: a new type of hereditary exertional myopathy. Clin Chim Acta. 1988;173:89\u201398.","journal-title":"Clin Chim Acta"},{"key":"549_CR132","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.semnephrol.2013.08.001","volume":"33","author":"M Noris","year":"2013","unstructured":"Noris M, Remuzzi G. Overview of complement activation and regulation. Semin Nephrol. 2013;33:479\u201392.","journal-title":"Semin Nephrol"},{"key":"549_CR133","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt1344","volume":"25","author":"RP Rother","year":"2007","unstructured":"Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25:1256\u201364.","journal-title":"Nat Biotechnol"},{"key":"549_CR134","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/j.molimm.2011.04.014","volume":"48","author":"TM Woodruff","year":"2011","unstructured":"Woodruff TM, Nandakumar KS, Tedesco F. Inhibiting the C5\u2013C5a receptor axis. Mol Immunol. 2011;48:1631\u201342.","journal-title":"Mol Immunol"},{"key":"549_CR135","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40262-020-00940-9","volume":"60","author":"P Badri","year":"2021","unstructured":"Badri P, Jiang X, Borodovsky A, Najafian N, Kim J, Clausen VA, et al. Pharmacokinetic and pharmacodynamic properties of cemdisiran, an RNAi therapeutic targeting complement component 5, in healthy subjects and patients with paroxysmal nocturnal hemoglobinuria. Clin Pharmacokinet. 2021;60:365\u201378.","journal-title":"Clin Pharmacokinet"},{"key":"549_CR136","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nm.3847","volume":"21","author":"A Sehgal","year":"2015","unstructured":"Sehgal A, Barros S, Ivanciu L, Cooley B, Qin J, Racie T, et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med. 2015;21:492\u20137.","journal-title":"Nat Med"},{"key":"549_CR137","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1616569","volume":"377","author":"KJ Pasi","year":"2017","unstructured":"Pasi KJ, Rangarajan S, Georgiev P, Mant T, Creagh MD, Lissitchkov T, et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med. 2017;377:819\u201328.","journal-title":"N Engl J Med"},{"key":"549_CR138","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2147\/JBM.S159297","volume":"9","author":"N Machin","year":"2018","unstructured":"Machin N, Ragni MV. An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B. J Blood Med. 2018;9:135\u201340.","journal-title":"J Blood Med."},{"key":"549_CR139","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1111\/jth.15270","volume":"19","author":"KJ Pasi","year":"2021","unstructured":"Pasi KJ, Lissitchkov T, Mamonov V, Mant T, Timofeeva M, Bagot C, et al. Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran: results of the phase 1 inhibitor cohort. J Thromb Haemost. 2021;19:1436\u201346.","journal-title":"J Thromb Haemost"},{"key":"549_CR140","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1182\/blood.V128.22.2572.2572","volume":"128","author":"MV Ragni","year":"2016","unstructured":"Ragni MV, Georgiev P, Mant T, Creagh MD, Lissitchkov T, Bevan D, et al. Fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia: updated results from a phase 1 and phase 1\/2 extension study in patients without inhibitors. Blood. 2016;128:2572.","journal-title":"Blood"},{"key":"549_CR141","doi-asserted-by":"publisher","first-page":"eabb3945","DOI":"10.1126\/scitranslmed.abb3945","volume":"13","author":"P Kumthekar","year":"2021","unstructured":"Kumthekar P, Ko CH, Paunesku T, Dixit K, Sonabend AM, Bloch O, et al. A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma. Science Transl Med. 2021;13:eabb3945.","journal-title":"Science Transl Med."},{"key":"549_CR142","doi-asserted-by":"publisher","first-page":"24560","DOI":"10.18632\/oncotarget.4183","volume":"6","author":"T Golan","year":"2015","unstructured":"Golan T, Khvalevsky EZ, Hubert A, Gabai RM, Hen N, Segal A, et al. RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. Oncotarget. 2015;6:24560\u201370.","journal-title":"Oncotarget"},{"key":"549_CR143","doi-asserted-by":"publisher","first-page":"TPS4672-TPS","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS4672","volume":"38","author":"AM Varghese","year":"2020","unstructured":"Varghese AM, Ang C, Dimaio CJ, Javle MM, Gutierrez M, Yarom N, et al. A phase II study of siG12D-LODER in combination with chemotherapy in patients with locally advanced pancreatic cancer (PROTACT). J Clin Oncol. 2020;38:TPS4672-TPS.","journal-title":"J Clin Oncol"},{"key":"549_CR144","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1097\/IAE.0b013e3181ad2341","volume":"29","author":"L Singerman","year":"2009","unstructured":"Singerman L. Combination therapy using the small interfering RNA bevasiranib. Retina. 2009;29:S49-50.","journal-title":"Retina"},{"key":"549_CR145","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4137\/OED.S4878","volume":"2","author":"AO Garba","year":"2010","unstructured":"Garba AO, Mousa SA. Bevasiranib for the treatment of wet, age-related macular degeneration. Ophthalmol Eye Dis. 2010;2:75\u201383.","journal-title":"Ophthalmol Eye Dis."},{"key":"549_CR146","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nature06765","volume":"452","author":"ME Kleinman","year":"2008","unstructured":"Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 2008;452:591\u20137.","journal-title":"Nature"},{"key":"549_CR147","doi-asserted-by":"publisher","first-page":"7137","DOI":"10.1073\/pnas.0812317106","volume":"106","author":"WG Cho","year":"2009","unstructured":"Cho WG, Albuquerque RJ, Kleinman ME, Tarallo V, Greco A, Nozaki M, et al. Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth. Proc Natl Acad Sci USA. 2009;106:7137\u201342.","journal-title":"Proc Natl Acad Sci USA"},{"key":"549_CR148","first-page":"111","volume":"90","author":"LJ Lu","year":"2017","unstructured":"Lu LJ, Tsai JC, Liu J. Novel pharmacologic candidates for treatment of primary open-angle glaucoma. Yale J Biol Med. 2017;90:111\u20138.","journal-title":"Yale J Biol Med"},{"key":"549_CR149","first-page":"564","volume":"55","author":"V Gonzalez","year":"2014","unstructured":"Gonzalez V, Palumaa K, Turman K, Mu\u00f1oz FJ, Jordan J, Garc\u00eda J, et al. Phase 2 of bamosiran (SYL040012), a novel RNAi based compound for the treatment of increased intraocular pressure associated to glaucoma. Invest Ophthalmol Vis Sci. 2014;55:564.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"549_CR150","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/13543784.2018.1457647","volume":"27","author":"J Moreno-Monta\u00f1\u00e9s","year":"2018","unstructured":"Moreno-Monta\u00f1\u00e9s J, Bleau AM, Jimenez AI. Tivanisiran, a novel siRNA for the treatment of dry eye disease. Exp Opin Invest Drugs. 2018;27:421\u20136.","journal-title":"Exp Opin Invest Drugs"},{"key":"549_CR151","doi-asserted-by":"publisher","first-page":"6447","DOI":"10.1167\/iovs.16-20303","volume":"57","author":"JM Benitez-Del-Castillo","year":"2016","unstructured":"Benitez-Del-Castillo JM, Moreno-Monta\u00f1\u00e9s J, Jim\u00e9nez-Alfaro I, Mu\u00f1oz-Negrete FJ, Turman K, Palumaa K, et al. Safety and efficacy clinical trials for SYL1001, a novel short interfering RNA for the treatment of dry eye disease. Invest Ophthalmol Vis Sci. 2016;57:6447\u201354.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"549_CR152","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1161\/CIRCULATIONAHA.120.053029","volume":"144","author":"M Thielmann","year":"2021","unstructured":"Thielmann M, Corteville D, Szabo G, Swaminathan M, Lamy A, Lehner LJ, et al. Teprasiran, a small interfering RNA, for the prevention of acute kidney injury in high-risk patients undergoing cardiac surgery: a randomized clinical study. Circulation. 2021;144:1133\u201344.","journal-title":"Circulation"},{"key":"549_CR153","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/35057062","volume":"409","author":"ES Lander","year":"2001","unstructured":"Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860\u2013921.","journal-title":"Nature"},{"key":"549_CR154","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1002\/1873-3468.13182","volume":"592","author":"E Lekka","year":"2018","unstructured":"Lekka E, Hall J. Noncoding RNAs in disease. FEBS Lett. 2018;592:2884\u2013900.","journal-title":"FEBS Lett"},{"key":"549_CR155","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nbt.2614","volume":"31","author":"G Sahay","year":"2013","unstructured":"Sahay G, Querbes W, Alabi C, Eltoukhy A, Sarkar S, Zurenko C, et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol. 2013;31:653\u20138.","journal-title":"Nat Biotechnol"},{"key":"549_CR156","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1038\/s41467-020-15300-1","volume":"11","author":"H Du Rietz","year":"2020","unstructured":"Du Rietz H, Hedlund H, Wilhelmson S, Nordenfelt P, Wittrup A. Imaging small molecule-induced endosomal escape of siRNA. Nat Commun. 2020;11:1809.","journal-title":"Nat Commun"},{"key":"549_CR157","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1038\/s41467-019-10562-w","volume":"10","author":"C Qiu","year":"2019","unstructured":"Qiu C, Han HH, Sun J, Zhang HT, Wei W, Cui SH, et al. Regulating intracellular fate of siRNA by endoplasmic reticulum membrane-decorated hybrid nanoplexes. Nat Commun. 2019;10:2702.","journal-title":"Nat Commun"},{"key":"549_CR158","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature22341","volume":"546","author":"S Kamerkar","year":"2017","unstructured":"Kamerkar S, LeBleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA, et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 2017;546:498\u2013503.","journal-title":"Nature"},{"key":"549_CR159","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jconrel.2019.12.032","volume":"319","author":"P Zhupanyn","year":"2020","unstructured":"Zhupanyn P, Ewe A, Buch T, Malek A, Rademacher P, Muller C, et al. Extracellular vesicle (ECV)-modified polyethylenimine (PEI) complexes for enhanced siRNA delivery in vitro and in vivo. J Control Release. 2020;319:63\u201376.","journal-title":"J Control Release"},{"key":"549_CR160","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","volume":"63","author":"J Fang","year":"2011","unstructured":"Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63:136\u201351.","journal-title":"Adv Drug Deliv Rev"},{"key":"549_CR161","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1038\/s41587-019-0351-4","volume":"37","author":"C Sheridan","year":"2019","unstructured":"Sheridan C. PCSK9-gene-silencing, cholesterol-lowering drug impresses. Nat Biotechnol. 2019;37:1385\u20137.","journal-title":"Nat Biotechnol"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00549-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-022-00549-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00549-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T07:42:56Z","timestamp":1663573376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-022-00549-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,23]]},"references-count":161,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["549"],"URL":"https:\/\/doi.org\/10.1007\/s40259-022-00549-3","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,23]]},"assertion":[{"value":"1 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Both authors contributed to the outlining, writing, and proofreading of this article.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}